The MenACYW-TT conjugate vaccine is a quadrivalent meningococcal vaccine that contains tetanus toxoid as carrier protein. The vaccine is intended for global use in all age groups (i.e., individuals 6 weeks of age and older). This Phase III study evaluated the immune lot consistency, and safety and immunogenicity of the vaccine when compared with a licensed quadrivalent meningococcal conjugate vaccine in individuals 10-55 years of age.
Background:
In the United States, most invasive meningococcal disease (IMD) is caused by serogroup B, followed by C, W, and Y. ACIP recommends universal vaccination against MenACWY (Category A) and MenB based on individual clinical decision-making (Category B) ( Figure 1 ). In 2017, MenACWY vaccine uptake among adolescents was 44.3% for ≥2 doses and MenB uptake was 14.5% for ≥1 dose of a multi-dose series. A pentavalent vaccine (MenABCWY or Penta) has the potential to simplify immunization schedules and improve uptake to achieve further reductions in IMD. Our objective was to estimate the potential public health impact of Penta.
Methods: Using CDC's enhanced meningococcal disease surveillance data (2015-2017 average), a dynamic transmission model was constructed to estimate the reduction in IMD over 10 years resulting from various implementation strategies including Penta within the existing United States meningococcal vaccination platform. The model assumed that 2-doses of Penta could provide 95% and 85% direct and 25.5% and 0% indirect protection, respectively, against serogroups ACWY and B for 5 years, with 10% relative waning per year. For partial compliance (1 dose Penta only), we assumed protection against ACWY equal to 2-doses but partial protection against B. Future uptake of Penta was assumed higher than 2017 uptake, and sensitivity analyses with lower uptake were conducted.
Results: Based on 2015-2017 epidemiology, the current schedule and uptake of MenACWY and MenB vaccines (total 4 doses) was estimated to avert 149 IMD cases over 10 years. Replacing MenACWY and/or MenB doses with Penta at 11 and/or 16 years could avert more cases, ranging from 172 to 243 ( Figure 2) . The most beneficial schedule was 2-doses of Penta at 11 years and 1-dose Penta at 16 years. Additional sensitivity analyses indicated that, even assuming current uptake rates, more cases could be prevented by utilizing Penta.
Conclusion: Replacing one or more MenACWY/MenB vaccine doses with Penta could improve prevention of IMD caused by all 5 meningococcal serogroups among the US adolescent population and provide substantial public health benefit while reducing the recommended number of vaccine administrations.
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US States' Policies for Meningococcal Vaccination vs. Disease Epidemiology
Methods: We researched requirements for meningococcal vaccination using state public health websites and national stakeholder materials (e.g., Immunization Action Coalition and their state chapters). Data as of November 2018 were compiled by vaccine type, age, and school/college requirements.
Results: Forty-five states and Washington DC require either meningococcal vaccination and/or vaccine education for school attendance (grades 6-12) and for college attendance. Thirty-one states require a MenACWY primary dose (at 11 years), of which 16 states also require the booster dose at 16 years (Table 1, Figure 1C ). One state requires MenB vaccination at 16-18 years. Of the 8 states that experienced college MenB outbreaks between 2013 and February 2019, all require vaccination or education for MenACWY but not MenB (Table 2 ). These differences in state requirements may underlie the reported adolescent vaccination coverage rates for MenACWY (85% for ≥ 1 dose, 44% for ≥ 2 doses) and MenB (14.5% for ≥ 1 dose of multidose series) vaccines, and additional reasons may be the efficiency of school-based vaccination programs, strength of the 11-year immunization platform, the more recent availability of MenB vs MenACWY vaccines, and disparate ACIP recommendations for these vaccines.
Conclusion: State vaccination requirements have helped catalyze MenACWY vaccine impact. Tailoring new requirements to the current epidemiology can help quell MenB disease and ensure that US adolescents are fully protected against meningococcal disease.
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